Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Has Consensus Price Target of $8.20

Key Points

• Analyst sentiment is cautious: Fulcrum Therapeutics has a consensus “Reduce” rating, with four sell, seven hold and one buy recommendation. The average 12-month price target is $8.20.
• Shares traded at $3.77, up 2.4% on Friday; they remain well below their 52-week high of $15.74. The company reported quarterly EPS of -$0.11, matching analysts’ consensus estimate.
• Institutional investors own 89.83% of the stock. Recent moves included BlackRock establishing a $32.3 million stake and Nantahala Capital increasing its holdings by 20.1%.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been assigned an average rating of "Reduce" from the twelve brokerages that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $8.20.

Several equities research analysts have issued reports on FULC shares. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of Fulcrum Therapeutics in a report on Thursday, October 15th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of FULC. BlackRock Inc. bought a new stake in Fulcrum Therapeutics in the second quarter valued at $32,297,000. Nantahala Capital Management LLC raised its holdings in Fulcrum Therapeutics by 20.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 6,575,352 shares of the company's stock worth $24,329,000 after purchasing an additional 1,100,312 shares in the last quarter. Siren L.L.C. lifted its position in shares of Fulcrum Therapeutics by 20.5% in the 1st quarter. Siren L.L.C. now owns 2,350,000 shares of the company's stock worth $18,024,000 after purchasing an additional 400,000 shares during the period. Marshall Wace LLP boosted its stake in shares of Fulcrum Therapeutics by 39.4% during the 3rd quarter. Marshall Wace LLP now owns 1,893,289 shares of the company's stock valued at $7,005,000 after purchasing an additional 534,866 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Fulcrum Therapeutics during the second quarter valued at about $5,728,000. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Stock Up 2.4%

NASDAQ FULC traded up $0.09 during trading hours on Friday, reaching $3.77. 1,364,507 shares of the company were exchanged, compared to its average volume of 1,300,025. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74. The business's 50 day simple moving average is $3.73 and its 200-day simple moving average is $5.55. The stock has a market capitalization of $287.95 million, a P/E ratio of -3.62 and a beta of 2.82.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts' consensus estimates of ($0.11). As a group, sell-side analysts anticipate that Fulcrum Therapeutics will post -0.60 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company's work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.